Sanmartí A, Permanyer-Miralda G, Castellanos J M, Foz-Sala M, Galard R M, Soler-Soler J
Am Heart J. 1984 Nov;108(5):1262-8. doi: 10.1016/0002-8703(84)90751-8.
In order to evaluate the effects of amiodarone on thyroid function in chronically treated patients, 43 consecutive patients, who had been taking a mean weekly dose of 1420 +/- 488 mg for more than 9 months (mean 16.5 months), were studied. In a first evaluation, three patients with hypothyroidism and two with hyperthyroidism were discovered. In the remaining 38 patients, mean T4 (131 +/- 38 nmol/L) and rT3 (0.85 +/- 0.3 nmol/L) levels were significantly higher than reference values (p less than 0.05 and p less than 0.001, respectively), and mean T3 levels (1.89 +/- 0.73 nmol/L) were significantly lower (p less than 0.001). Thirteen patients showed hyperresponsiveness to thyrotropin-releasing hormone (TRH) stimulation testing. In a second evaluation, performed 12 to 18 months later, two new cases of hypothyroidism were discovered. T3 levels showed significantly lower values (p less than 0.02) than in the first evaluation, whereas basal thyroid-stimulating hormone levels and levels 30 and 60 minutes after TRH stimulation were significantly higher than those in the first evaluation (p less than 0.001). Five new hyperresponders to TRH were found. In the present series, the progressive appearance of clinical thyroid dysfunction with an elevated total incidence (16%) is demonstrated. Moreover, a progressively high prevalence of hyperresponsiveness to TRH stimulation is shown. These findings indicate that chronic amiodarone administration may carry a high risk of thyroid dysfunction.
为了评估胺碘酮对长期治疗患者甲状腺功能的影响,我们对43例连续患者进行了研究,这些患者平均每周服用1420±488毫克胺碘酮超过9个月(平均16.5个月)。在首次评估中,发现3例甲状腺功能减退患者和2例甲状腺功能亢进患者。在其余38例患者中,平均T4(131±38纳摩尔/升)和反T3(0.85±0.3纳摩尔/升)水平显著高于参考值(分别为p<0.05和p<0.001),而平均T3水平(1.89±0.73纳摩尔/升)显著较低(p<0.001)。13例患者对促甲状腺激素释放激素(TRH)刺激试验表现出高反应性。在12至18个月后进行的第二次评估中,又发现了2例甲状腺功能减退新病例。T3水平显示出比首次评估时显著更低的值(p<0.02),而基础促甲状腺激素水平以及TRH刺激后30分钟和60分钟的水平显著高于首次评估时(p<0.001)。发现了5例对TRH的新的高反应者。在本系列研究中,证实了临床甲状腺功能障碍逐渐出现且总发生率升高(16%)。此外,显示出对TRH刺激的高反应性患病率逐渐升高。这些发现表明,长期服用胺碘酮可能具有较高的甲状腺功能障碍风险。